Aptose Biosciences (APTO)
(Delayed Data from NSDQ)
$0.67 USD
-0.03 (-4.41%)
Updated Jul 16, 2024 03:59 PM ET
After-Market: $0.68 +0.01 (1.19%) 7:30 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
APTO 0.67 -0.03(-4.41%)
Will APTO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for APTO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APTO
Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock?
What Makes Aptose Biosciences (APTO) a New Buy Stock
APTO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why
Are Medical Stocks Lagging Annovis Bio (ANVS) This Year?
Deciphera (DCPH) Rises 90% in the Past 6 Months: Here's Why
Other News for APTO
Aptose Announces Results from Annual and Special Meeting of Shareholders
Aptose Biosciences Shareholders Approve Key Proposals
Tuspetinib: A Promising Candidate for Enhancing r/r AML Treatment Outcomes
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
Aptose Biosciences Issues Non-Filed Information Disclosure